PARIS/LONDON Nov 26 (Reuters): Novo Nordisk last week announced a $2.3 billion investment to boost production of its wildly popular weight-loss and diabetes drugs at a site in Chartres, France as it races to meet soaring demand.
The investment will significantly increase production capacity for current medicines including Ozempic and Wegovy as well as other obesity treatments that are being developed, the Danish drugmaker said.
There is a growing crisis in Europe over supply of diabetes therapy Ozempic, which uses the same ingredient semaglutide as the hugely popular weight-loss drug Wegovy, which is not yet widely available in Europe.
Novo this week introduced curbs on the use of Ozempic, which is also widely used for weight loss, in the European Union because of this 'off label' use. Germany is considering banning exports of the drug. Belgium has banned prescriptions of the weekly injection unless they are for type 2 diabetes patients.
Novo Nordisk invests $2.3b France to boost obesity drug production
FE Team | Published: November 26, 2023 22:35:08
Novo Nordisk invests $2.3b France to boost obesity drug production
Share if you like